WO1999020606A3 - Piperidines and piperazines as platelet aggregation inhibitors - Google Patents

Piperidines and piperazines as platelet aggregation inhibitors Download PDF

Info

Publication number
WO1999020606A3
WO1999020606A3 PCT/EP1998/006751 EP9806751W WO9920606A3 WO 1999020606 A3 WO1999020606 A3 WO 1999020606A3 EP 9806751 W EP9806751 W EP 9806751W WO 9920606 A3 WO9920606 A3 WO 9920606A3
Authority
WO
WIPO (PCT)
Prior art keywords
platelet aggregation
piperazines
piperidines
aggregation inhibitors
compounds
Prior art date
Application number
PCT/EP1998/006751
Other languages
French (fr)
Other versions
WO1999020606A2 (en
Inventor
Elena Carceller
Pere J Jimenez
Jorge Salas
Original Assignee
Uriach & Cia Sa J
Elena Carceller
Pere J Jimenez
Jorge Salas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uriach & Cia Sa J, Elena Carceller, Pere J Jimenez, Jorge Salas filed Critical Uriach & Cia Sa J
Priority to AU21513/99A priority Critical patent/AU2151399A/en
Publication of WO1999020606A2 publication Critical patent/WO1999020606A2/en
Publication of WO1999020606A3 publication Critical patent/WO1999020606A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Compounds of formula (I) and their salts, solvates and prodrugs are platelet aggregation inhibitors and are useful for the treatment or prevention of thromboembolic disorders. Pharmaceutical compositions including these compounds and processes for their preparation are also provided.
PCT/EP1998/006751 1997-10-23 1998-10-23 Piperidines and piperazines as platelet aggregation inhibitors WO1999020606A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21513/99A AU2151399A (en) 1997-10-23 1998-10-23 Novel piperidines and piperazines as platelet aggregation inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP9702188 1997-10-23
ES9702188 1997-10-23

Publications (2)

Publication Number Publication Date
WO1999020606A2 WO1999020606A2 (en) 1999-04-29
WO1999020606A3 true WO1999020606A3 (en) 1999-07-29

Family

ID=8300941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006751 WO1999020606A2 (en) 1997-10-23 1998-10-23 Piperidines and piperazines as platelet aggregation inhibitors

Country Status (3)

Country Link
AR (1) AR013693A1 (en)
AU (1) AU2151399A (en)
WO (1) WO1999020606A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2380817A1 (en) * 1999-08-13 2001-02-22 Biogen, Inc. Cell adhesion inhibitors
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
EP1830837B1 (en) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051090A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003325A (en) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors.
BRPI0515482A (en) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc heterocyclic derivatives and their uses as therapeutic agents
AR051094A1 (en) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
KR20070107040A (en) 2005-02-16 2007-11-06 쉐링 코포레이션 Heteroaryl substituted pyrazinyl-piperazine-piperidlnes with cxcr3 antagonist activity
KR20070107075A (en) 2005-02-16 2007-11-06 쉐링 코포레이션 Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
US7868005B2 (en) 2005-02-16 2011-01-11 Schering Corporation Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
CN101189238A (en) 2005-02-16 2008-05-28 先灵公司 Piperazine-piperidines with CXCR3 antagonist activity
CN101213185A (en) 2005-02-16 2008-07-02 先灵公司 Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
JP2009513563A (en) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2007087066A2 (en) 2005-12-28 2007-08-02 Vertex Pharmaceuticals Incorporated 1-(benzo [d] [1,3] di0x0l-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
AR059224A1 (en) * 2006-01-31 2008-03-19 Jerini Ag COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
WO2007109238A1 (en) 2006-03-21 2007-09-27 Schering Corporation Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
KR20090043512A (en) 2006-07-14 2009-05-06 쉐링 코포레이션 Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity
WO2008076243A2 (en) 2006-12-14 2008-06-26 Merck & Co., Inc. Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment
US9181226B2 (en) * 2011-07-18 2015-11-10 Merck Patent Gmbh Benzamides
CN106543089A (en) * 2016-11-04 2017-03-29 山东铂源药业有限公司 A kind of synthetic method of Dasatinib intermediate

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441226A1 (en) * 1990-01-29 1991-08-14 J. URIACH & CIA. S.A. (cyanomethyl)pyridines useful as PAF antagonists
EP0528172A1 (en) * 1991-08-08 1993-02-24 J. URIACH & CIA. S.A. (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists
EP0542363A2 (en) * 1991-11-14 1993-05-19 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1993014077A1 (en) * 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0560669A1 (en) * 1992-03-11 1993-09-15 Bristol-Myers Squibb Company Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes
US5563141A (en) * 1993-03-29 1996-10-08 Zeneca Limited Heterocyclic compounds
DE19524765A1 (en) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh New oxazolidinone derivatives, processes for their preparation and medicaments containing these compounds
WO1997002245A1 (en) * 1995-07-06 1997-01-23 Japan Tobacco Inc. Benzamidoxime derivatives and medicinal use thereof
WO1997026258A1 (en) * 1996-01-15 1997-07-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441226A1 (en) * 1990-01-29 1991-08-14 J. URIACH & CIA. S.A. (cyanomethyl)pyridines useful as PAF antagonists
EP0528172A1 (en) * 1991-08-08 1993-02-24 J. URIACH & CIA. S.A. (2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists
EP0542363A2 (en) * 1991-11-14 1993-05-19 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
WO1993014077A1 (en) * 1992-01-21 1993-07-22 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
EP0560669A1 (en) * 1992-03-11 1993-09-15 Bristol-Myers Squibb Company Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes
US5352678A (en) * 1992-03-11 1994-10-04 Bristol-Myers Squibb Co. Antiischemic piperazinyl- and piperidinyl-cyclohexanes
US5563141A (en) * 1993-03-29 1996-10-08 Zeneca Limited Heterocyclic compounds
WO1997002245A1 (en) * 1995-07-06 1997-01-23 Japan Tobacco Inc. Benzamidoxime derivatives and medicinal use thereof
DE19524765A1 (en) * 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh New oxazolidinone derivatives, processes for their preparation and medicaments containing these compounds
WO1997026258A1 (en) * 1996-01-15 1997-07-24 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. ALIG ET AL.: "Low Molecular Weight, Non-peptide Fibrinogen Receptor Antagonists", J. MED. CHEM., vol. 35, no. 23, 1992, pages 4393 - 4407, XP000561169 *

Also Published As

Publication number Publication date
AU2151399A (en) 1999-05-10
AR013693A1 (en) 2001-01-10
WO1999020606A2 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
WO1999020606A3 (en) Piperidines and piperazines as platelet aggregation inhibitors
WO2001098277A3 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
CA2333703A1 (en) Isothiazole derivatives useful as anticancer agents
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2274464A1 (en) Ketobenzamides as calpain inhibitors
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
MY128659A (en) Novel aminodicarboxylic acid derivatives having pharmaceutical properties
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
HK1068136A1 (en) Muscarinic antagonists
CA2343236A1 (en) 4,4-biarylpiperidine derivatives
CA2356300A1 (en) 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GEP20074221B (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
WO2002098856A3 (en) Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
HK1155146A1 (en) Indene derivatives as pharmaceutical agents
WO2001029055A3 (en) Novel oligosaccharides, preparation method and pharmaceutical compositions containing same
AU3495397A (en) Muscarinic antagonists
WO2002048148A3 (en) Pyrazolopyridine derivatives
WO2002018379A3 (en) 7-oxo pyridopyrimidines
ES2087038A1 (en) Novel piperidine derivatives with paf antagonist activity
IL151201A0 (en) Alkylated imidazopyridine derivatives and pharmaceutical compositions containing the same
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
WO2003053971A8 (en) Pyridoquinoxaline antivirals
IL151200A0 (en) Tricyclic imidazopyridine prodrug derivatives and pharmaceutical compositions containing the same
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA